Loading…
VENTOLIN I.V. is a brand name for Albuterol (also known as Salbutamol), supplied as a solution. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS…
Verbatim from this product's HC label. Tap a section to expand.
V. infusion solution is contraindicated in: Patients who are hypersensitive to this drug or to any ingredient in the formulation or component of the container (see DOSAGE FORMS, COMPOSITION AND PACKAGING). Patients with cardiac tachyarrhythmias.
As a tocolytic in patients at risk of premature labour or threatened abortion. WARNINGS AND PRECAUTIONS General The dosage or frequency of administration should only be increased on medical advice. V. infusion solution may also be receiving short-acting inhaled bronchodilators to relieve symptoms.
Increasing use of bronchodilators, in particular short-acting inhaled beta2-agonists to relieve symptoms, indicates deterioration of asthma control. Sudden or progressive deterioration in asthma control is potentially life threatening; the treatment plan must be re-evaluated, and consideration be given to corticosteroid therapy.
The use of VENTOLIN® infusion solution in the treatment of severe bronchospasm does not obviate the requirement for corticosteroid therapy as appropriate. When practicable, administration of oxygen, concurrently with VENTOLIN® infusion solution is recommended, particularly when salbutamol is given by intravenous infusion to hypoxic patients.
V. infusion solution should be used with caution in patients, particularly pregnant women, with pre-existing ischaemic heart disease or with significant risk factors for ischaemic heart disease (see WARNINGS AND PRECAUTIONS, Special Populations, Pregnant Women).
In individual patients, any beta2-adrenergic agonist, including salbutamol, may have a clinically significant cardiac effect. Care should be taken with patients suffering from cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias and hypertension.
Special care and supervision are required in patients with idiopathic hypertrophic subvalvular aortic stenosis, in whom an increase in the pressure gradient between the left ventricle and the aorta may occur, causing increased strain on the left ventricle.
Fatalities have been reported following excessive use of inhaled sympathomimetic drugs in patients with asthma. doc Page 5 of 22 following an unexpected development of a severe acute asthmatic crisis and subsequent hypoxia is suspected.
Cardiovascular effects may be seen with sympathomimetic drugs, including salbutamol. There is some evidence from post-marketing data and published literature of rare occurrences of myocardial ischaemia associated with salbutamol. g. ischaemic heart disease, arrhythmia or severe heart failure) who are receiving salbutamol should be warned to seek medical advice if they experience chest pain or other symptoms of worsening heart disease.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Albuterol in Canada.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
Attention should be paid to assessment of symptoms such as dyspnea and chest pain, as they may be of either respiratory or cardiac origin. Endocrine and Metabolism Metabolic Effects In common with other beta-adrenergic agents, salbutamol can induce reversible metabolic changes, such as potentially serious hypokalemia, particularly following infused administration.
Particular caution is advised in acute severe asthma since hypokalemia may be potentiated by concomitant treatment with xanthine derivatives, steroids and diuretics, and by hypoxia. Hypokalemia will increase the susceptibility of digitalis-treated patients to cardiac arrhythmias.
It is recommended that serum potassium levels be monitored in such situations. Large doses of intravenous salbutamol have been reported to aggravate pre-existing diabetes mellitus. The diabetic patient may be unable to compensate for the increased blood glucose levels and the development of ketoacidosis has been reported.
Concurrent administration of corticosteroids can exaggerate this effect. V. g. an increase in insulin dosage) can be taken to counter any metabolic change that is occurring. V. infusion solution should be diluted with Sodium Chloride Injection, rather than Sodium Chloride and Dextrose Injection.
Lactic acidosis has been reported very rarely in association with high therapeutic doses of intravenous and nebulised short-acting beta-agonist therapy, mainly in patients being treated for an acute asthma exacerbation (see Adverse Reaction section).
Increase in lactate levels may lead to dyspnea and compensatory hyperventilation, which could be misinterpreted as a sign of asthma treatment failure and lead to inappropriate intensification of short-acting beta-agonist treatment.
It is therefore recommended that patients are monitored for the development of elevated serum lactate and consequent metabolic acidosis in this setting. Care should be taken with patients with hyperthyroidism. doc Page 6 of 22 Hypersensitivity Immediate hypersensitivity reactions may occur after administration of salbutamol, as demonstrated by rare cases of urticaria, angioedema, rash, bronchospasm, hypotension, anaphylaxis and oropharyngeal edema.
Care should be taken in patients who are unusually responsive to sympathomimetic amines. Neurologic Care should be taken with patients with convulsive disorders.
Special Populations Pregnant Women:
Salbutamol, in common with other beta-mimetics, is not approved to stop or prevent premature labour. Due to the risk of pulmonary edema and myocardial ischaemia that has been observed during the use of betamimetics in the treatment of premature labour, before VENTOLIN® infusion solution is given to any patient with known or suspected heart disease, an adequate assessment of […]